Celdara Medical, LLC today announced that the first DRIVEN Accelerator Hub Participant Company, CairnSurgical, Inc., has closed a Series A investment led by Morningside Group. The CairnSurgical team first engaged with both the DRIVEN External Advisory Committee (representing over $10B in assets under management and over $700B in cumulative market cap), and the DRIVEN Internal Advisory Committee (representing each of the leading research institutions in the region) at the inaugural DRIVEN meeting in January 2019. Jake Reder, PhD, Celdara’s CEO and Principal Investigator of the DRIVEN Hub, stated, “I am gratified to see the CairnSurgical team achieve this key milestone, and even better to do so with such a forward-thinking investment firm. Their outstanding team and excellent clinical data have already demonstrated the potential to improve breast cancer surgical outcomes and patient lives. This investment further accelerates their growth and impact. We’re all very proud of CairnSurgical’s successes! More broadly, this is an excellent example of the power in connecting local innovation with sophisticated global capital.”
System Designed to Reduce the Incidence of Positive Margins – or Cancer Left Behind - After Breast Cancer Surgery
The Breast Cancer Locator™ from Cairn Surgical has been named the 2021 Product of the Year by the NH Tech...
CairnSurgical: Patient-Specific, Real-Time Guidance for Breast Cancer Surgery